OverviewChartNewsTraderScreen

Morgan Stanley Call 400 MDGL 20.1.../  DE000MG0D862  /

Stuttgart
2024-06-07  5:47:00 PM Chg.+0.010 Bid10:00:33 PM Ask10:00:33 PM Underlying Strike price Expiration date Option type
0.530EUR +1.92% -
Bid Size: -		 -
Ask Size: -		 Madrigal Pharmaceuti... 400.00 USD 2024-12-20 Call
GlobeNewswire 06-06 Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resme...
GlobeNewswire 06-05 Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conferenc...
GlobeNewswire 05-29 Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes R...
GlobeNewswire 05-22 Anavex Life Sciences Announces Expansion of Leadership Team
GlobeNewswire 05-07 Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 04-24 Madrigal Statement on the Passing of Dr. Stephen Harrison
GlobeNewswire 04-23 Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, ...
GlobeNewswire 04-16 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 04-09 Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of...
GlobeNewswire 04-05 US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for ...
GlobeNewswire 04-04 GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 04-03 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 03-19 Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
GlobeNewswire 03-18 Madrigal Pharmaceuticals Announces Proposed Public Offering
GlobeNewswire 03-14 FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
GlobeNewswire 03-14 Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Pati...
GlobeNewswire 03-06 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 03-05 Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Res...
GlobeNewswire 02-28 Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
GlobeNewswire 02-28 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Fi...
GlobeNewswire 02-21 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 02-08 Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in th...
GlobeNewswire 02-06 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 01-29 Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
GlobeNewswire 01-22 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)